Maternal buprenorphine treatment and fetal neurobehavioral development

• DOI: 10.1016/j.ajog.2017.01.040
• Publication Date: 2017-02-07T13:48:29Z
• Authors: Lauren M. Jansson; Martha Velez; Krystle McConnell; Nancy Spencer; Michelle Tuten; Hendree E. Jones; Van L. King; Neeraj Gandotra; Lorraine A. Milio; Kristin Voegtline; Janet A. DiPietro
• Keywords: Cardiotocography; Dose-Response Relationship, Drug; Narcotic Antagonists; Smoking; Gestational Age; Heart Rate, Fetal; Opioid-Related Disorders; Buprenorphine; 3. Good health; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Pregnancy; Opiate Substitution Treatment; Humans; Female; Fetal Movement

(Am J Obstet Gynecol. 2017;216(5):529.e1–529.e8) Opioid usage is increasing among pregnant mothers in the United States, which can lead to neonatal abstinence syndrome in their children. Previous studies have shown less severe neonatal abstinence syndrome in infants whose mothers were treated for opioid use with buprenorphine rather than methadone. This study looked at the effects of buprenorphine on fetal activity and development.